Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes

BCL2 blockade overcomes MCL1 resistance in multiple myeloma

(2019) Ka Tat Siu et al.   LEUKEMIA

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma

(2019) Shannon M. Matulis et al.   LEUKEMIA

Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

(2019) Esperanza M Algarín et al.   HAEMATOLOGICA

Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)

(2019) Dawn Swan et al.   HAEMATOLOGICA

Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells

(2018) Justine Debernardi et al.   ONCOGENE

Parallel derivation of isogenic human primed and naive induced pluripotent stem cells

(2018) Stéphanie Kilens et al.   Nature Communications

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia

(2018) Donia M. Moujalled et al.   LEUKEMIA

A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia

(2018) Haley E. Ramsey et al.   Cancer Discovery

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways

(2018) Benoît Tessoulin et al.   Journal of Hematology & Oncology

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

(2018) Adriana E. Tron et al.   Nature Communications

Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia

(2018) Piers Blombery et al.   Cancer Discovery

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)

(2017) Cyrille Touzeau et al.   HAEMATOLOGICA

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)

(2017) Cyrille Touzeau et al.   HAEMATOLOGICA

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1

(2016) J.-N. Gong et al.   BLOOD

Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia

(2016) Patrick D. Bhola et al.   JOURNAL OF CLINICAL INVESTIGATION

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines

(2015) Sophie Maïga et al.   CYTOMETRY PART A

BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics

(2015) C Touzeau et al.   LEUKEMIA

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma

(2015) Charlotte Kervoëlen et al.   Oncotarget

NbClust: AnRPackage for Determining the Relevant Number of Clusters in a Data Set

(2015) Malika Charrad et al.   Journal of Statistical Software

Bax targets mitochondria by distinct mechanisms before or during apoptotic cell death: a requirement for VDAC2 or Bak for efficient Bax apoptotic function

(2014) S B Ma et al.   CELL DEATH AND DIFFERENTIATION

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

(2013) C Touzeau et al.   LEUKEMIA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

ABT-737 is highly effective against molecular subgroups of multiple myeloma

(2011) L. Bodet et al.   BLOOD

A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria

(2011) Fabien Llambi et al.   MOLECULAR CELL